MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.

    H. Berven, S. Kverneng, E. Sheard, M. Søgnen, S. Geijerstam, K. Haugarvoll, GO. Skeie, C. Dölle, C. Tzoulis (Bergen, Norway)

    Objective: To determine the safety of oral nicotinamide riboside (NR) 3000 mg daily for 4 weeks in Parkinson’s disease (PD). Secondary objectives: To assess NRs…
  • 2023 International Congress

    Altered cognitive control processes in the prodromal phase of X-linked dystonia-parkinsonism (XDP)

    M. Heldmann, J. Steinhardt, J. Dy, A. Sprenger, J. Tantianpact, H. Hanssen, R. Tuazon, R. Rosales, A. Westenberger, J. Oropilla, N. Brüggemann, C. Diesta (Lübeck, Germany)

    Objective: Investigating non-manifesting carriers (NMC) of the TAF1 gene mutation causing X-linked dystonia-parkinsonism to reveal a potential change in the neural basis of cognitive control processes during…
  • 2023 International Congress

    Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.

    J. Wallin, P. Svenningsson (Stockholm, Sweden)

    Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…
  • 2023 International Congress

    Why is HAL effective in improving gait and balance function in Parkinson’s disease?

    N. Togashi, K. Tateno, Y. Kondo, M. Masanobu, A. Kawanami, K. Hasegawa (Sagamihara, Japan)

    Objective: We performed rehabilitation using a Hybrid Assisted Limb (HAL) for PD and found that gait and balance functions improved before and after HAL rehabilitation.…
  • 2023 International Congress

    Genetic polymorphisms associated with nigrostriatal dopaminergic depletion as measured with [I123]-FP-CIT SPECT in Parkinson’s disease

    S. Castro Labrador, MA. Labrador Espinosa, J. Silva Rodríguez, D. García Solís, P. Mir, MJ. Grothe (Seville, Spain)

    Objective: To conduct a genome-wide association study (GWAS) of striatal [I123]-FP-CIT SPECT signal as endophenotype to explore possible associations between genetic background and nigrostriatal dopaminergic…
  • 2023 International Congress

    motor and non-motor correlates of hyposmia detected by the italian olfactory identification test (ioit) in an italian cohort of parkinson’s disease patients

    A. Mechelli, N. Tambasco, M. Filidei, C. Maremmani, M. Pierini, P. Nigro, S. Simoni, L. Parnetti (Catanzaro, Italy)

    Objective: To characterize olfaction in a cohort of PD patients and to investigate the relationship between olfactory impairment with both motor and non-motor features and other clinical characteristics…
  • 2023 International Congress

    Early functional disruption in body-first compared to brain-first Parkinson’s disease

    M. Conti, R. Bovenzi, R. Cerroni, T. Schirinzi, M. Pierantozzi, N. Mercuri, A. Stefani (Rome, Italy)

    Objective: To analyze differences in functional connectivity (FC) between Parkinson’s disease (PD) patients with and without premotor REM behavior disorder (pRBD), by means of high-density…
  • 2023 International Congress

    Clinico-genetic analysis of patients with Parkinson’s disease and GBA mutations from a tertiary care teaching centre in India

    S. Kamath, V. Holla, P. Phulpagar, N. Kamble, R. Yadav, B. Muthusamy, PK. Pal (Bangalore, India)

    Objective: To describe the clinico-genetic association of PD patients with heterozygous GBA mutations (PDwG). Background: Parkinson’s disease (PD) is currently understood to be the outcome…
  • 2023 International Congress

    Isolation of L1CAM-extracellular vesicles reveals signs of insulin resistance in Parkinson’s disease

    I. Markaki, W. Paslawski, T. Ntetsika, P. Svenningsson (Stockholm, Sweden)

    Objective: The aim of this study was to test the utility of isolating L1 Cell Adhesion Molecule (L1CAM)-derived extracellular vesicles (EVs) in quantification of glucose…
  • 2023 International Congress

    A Novel Real Time Algorithm to Predict Freezing of Gait in Parkinson’s Patients Using Wearable Mobility Sensors Data

    N. Galor, T. Krasovsky, S. Hassin, B. Heimler, M. Plotnik (Ramat Gan, Israel)

    Objective: To develop an algorithm for real-time Freezing of gait (FOG) prediction based on the online monitoring of the stepping coherence. Background: FOG is a…
  • « Previous Page
  • 1
  • …
  • 381
  • 382
  • 383
  • 384
  • 385
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley